Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug

Sage Therapeutics unveiled promising results for its Biogen-partnered essential tremors treatment known as SAGE-324 on Monday, but Sage stock tripped on worse-than-expected side effects.
Read More